1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 90 F.Supp.2d
  5. 90 F.Supp.2d 522 (2000)
 

BRISTOL-MYERS SQUIBB CO. v. BEN VENUE LABORATORIES

Nos. CIV. A. 97-6050 (WHW), 98-159(WHW), 98-1412(WHW), 98-1488(WHW) and 98-2827(WHW).

90 F.Supp.2d 522 (2000)

BRISTOL-MYERS SQUIBB COMPANY, Plaintiff, v. BEN VENUE LABORATORIES, Bedford Laboratories, Immunex Corporation, Zenith Goldline Pharmaceuticals, Inc., Ivax Corporation, Mylan Pharmaceuticals, Schein Pharmaceuticals, Marsam Pharmaceuticals, Defendants.

United States District Court, D. New Jersey.

March 17, 2000.

INTRODUCTION and BACKGROUND

WALLS, District Judge.

Plaintiff Bristol-Myers Squibb Company ("Bristol") moves for summary judgment that U.S. Patent Nos. 5,641,803 ("the '803 patent") and 5,670,537 ("the '537 patent") are not unenforceable due to inequitable conduct. Defendants and counterclaimants, Zenith Goldline Pharmaceuticals, Inc., IVAX Corporation, Baker...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases